In the special “GENETIC INSTABILITY” of Swiss Oncology in Motion, Prof. Dr. med. Viola Heinzelmann-Schwarz (University Hospital Basel), Prof. Dr. med. Jens Huober (Canton Hospital St. Gallen), PD Dr. med. Aurelius Omlin (OnkoZentrum Zürich), Prof. Dr. med. Dr. phil. Andreas Wicki (University Hospital Zurich) and Prof. Dr. med. Wolfram Jochum (Cantonal Hospital St. Gallen) discussed the role of genetic instability in various tumor types, in particular ovarian and endometrial carcinomas, breast carcionoma, GI tumors, and prostate, urothelial, and renal cell carcinomas, and how it influences treatment options. The discussion will be led by Prof. em. Richard Herrmann, MD, Basel, moderated.
You May Also Like
- Evidence, limitations and practical implications
Phytotherapy for anxiety disorders
- Case report: Hiccups after ketoacidosis
Nebulized lidocaine brings relief
- Hidradenitis suppurativa: biologics reduce inflammatory processes
Treatment recommendations depend on the severity and inflammatory activity
- Dizziness as a leading symptom: new consensus paper
Current recommendations for handling in everyday practice
- Endometrial carcinoma, malignant melanoma and NSCLC in focus
Personalized mRNA and neoantigen vaccines in oncology
- Consequences for pathophysiology, clinic and therapy
The inflammatory subgroup of major depression
- Adherence of GLP1-RA
Half of patients discontinue treatment within a year
- RSV infection in adult patients at risk